## **CORDLIFE GROUP LIMITED**

(Company Registration No.: 200102883E) (Incorporated in the Republic of Singapore) (the "<u>Company</u>")

## UNSOLICITED OFFER TO ACQUIRE SHARES IN CHINA CORD BLOOD CORPORATION AND 7% SENIOR UNSECURED CONVERTIBLE NOTE DUE 2017

The Board of Directors of the Company (the "Board") refers to the Company's announcement on 7 July 2015 relating to the receipt of an unsolicited offer (the "Offer") from a third party to acquire the 7,314,015 ordinary shares of par value US\$0.0001 per share in China Cord Blood Corporation ("CCBC") and the 7% senior unsecured convertible note due 3 October 2017 issued by CCBC to the Company in the principal amount of US\$25 million (the shares and the convertible note collectively, the "Assets"), which the Company had agreed to sell to Golden Meditech Holdings Limited (the "Purchaser"), pursuant to a conditional purchase agreement dated 8 May 2015 (the "Agreement") between the Company and the Purchaser. As announced, the Board had decided to reject the Offer after due and careful consideration.

The Board wishes to announce that the Board has received a second offer for the Assets from the same third party on revised terms (the "Revised Offer").

The Board is presently reviewing the Revised Offer.

Shareholders of the Company are advised to exercise caution when dealing in the shares of the Company and refrain from taking any action in relation to their shares of the Company which may be prejudicial to their interests until they have considered the information as set out in a circular to shareholders to be issued by the Company in due course.

The Board will make appropriate announcements at the relevant time should circumstances merit such announcements.

By Order of the Board

CORDLIFE GROUP LIMITED

Mr. Yee Pinh Jeremy Director 3 August 2015